文献速递消化、代谢与肾脏急症复苏、休克与脓毒症

静脉氨甲环酸治疗消化道出血:随机对照试验的系统评价与荟萃分析

Intravenous tranexamic acid in gastrointestinal bleeding: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Am J Emerg Med · 2025-07-23
一句话结论静脉氨甲环酸可降低消化道出血患者的再出血率和止血失败率,但不降低死亡率,且需警惕血栓栓塞风险。

该系统评价与荟萃分析纳入7项随机对照试验共13608例成人消化道出血患者,评估静脉氨甲环酸(TXA)的疗效与安全性。结果显示,TXA显著降低再出血率(OR 0.64;95%CI:0.45-0.91,P=0.01)和止血失败率(OR 0.55;95%CI:0.45-0.91,P=0.03),但未显著降低死亡率(OR 0.77;95%CI:0.56-1.07,P=0.12)或输血需求(OR 0.94;95%CI:0.61-1.43,P=0.76)。血栓栓塞事件在随机效应模型中无显著差异(OR 1.28;95%CI:0.51-4.51,P=0.46),但固定效应分析提示有统计学意义(OR 1.28;95%CI:1.07-1.55,P=0.009)。作者认为静脉TXA似乎是有效的辅助治疗,但需谨慎对待潜在血栓栓塞风险,需进一步研究优化使用并识别高危人群。

要点

  • 静脉氨甲环酸显著降低消化道出血患者再出血率(OR 0.64;95%CI:0.45-0.91,P=0.01)。
  • 静脉氨甲环酸显著降低止血失败率(OR 0.55;95%CI:0.45-0.91,P=0.03)。
  • 静脉氨甲环酸未显著降低死亡率(OR 0.77;95%CI:0.56-1.07,P=0.12)。
  • 静脉氨甲环酸未显著减少输血需求(OR 0.94;95%CI:0.61-1.43,P=0.76)。
  • 血栓栓塞事件随机效应模型无显著差异(OR 1.28;95%CI:0.51-4.51,P=0.46),固定效应分析提示有统计学意义(OR 1.28;95%CI:1.07-1.55,P=0.009)。

适用人群与场景

  • 成人消化道出血患者(纳入7项随机对照试验的成人患者)。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,遵循PRISMA指南,纳入7项随机对照试验,共13608例成人消化道出血患者。
  • 主要终点:再出血率显著降低(OR 0.64;95%CI:0.45-0.91,P=0.01);止血失败率显著降低(OR 0.55;95%CI:0.45-0.91,P=0.03)。
  • 次要终点:死亡率无显著降低(OR 0.77;95%CI:0.56-1.07,P=0.12);输血需求无显著减少(OR 0.94;95%CI:0.61-1.43,P=0.76)。
  • 不良事件:血栓栓塞事件随机效应模型无显著差异(OR 1.28;95%CI:0.51-4.51,P=0.46),固定效应分析提示有统计学意义(OR 1.28;95%CI:1.07-1.55,P=0.009)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入7项随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为静脉氨甲环酸似乎是消化道出血的有效辅助治疗,尤其可减少再出血和止血失败。
  • 作者认为需谨慎对待潜在血栓栓塞风险,需进一步研究优化氨甲环酸使用并识别高危人群。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Gastrointestinal bleeding is a critical condition associated with high morbidity and mortality, necessitating effective management strategies. Tranexamic acid (TXA), an anti-fibrinolytic agent, has been proposed as a therapeutic option to reduce bleeding complications. However, recent randomized controlled trials (RCTs) have produced conflicting results regarding its efficacy and safety.

METHOD: This systematic review and meta-analysis followed PRISMA guidelines and included RCTs evaluating the use of intravenous TXA in adult patients with gastrointestinal bleeding. Comprehensive searches were conducted in PubMed and Google Scholar, yielding 518 publications, with 7 RCTs meeting inclusion criteria. Data were synthesized using mainly a random-effects model to assess outcomes, including mortality, rebleeding, failure to control bleeding, thromboembolic events, and blood transfusion requirements.

RESULT: The analysis included 7 RCTs of 13,608 participants, revealing that IV TXA was statistically significant in reducing rebleeding rates (OR 0.64; 95 % CI: 0.45-0.91, P = 0.01) and failure to control bleeding (OR 0.55; 95 % CI: 0.45-0.91, P = 0.03). However, there was no significant reduction in mortality (OR 0.77; 95 % CI: 0.56-1.07, P = 0.12) or blood transfusion requirements (OR 0.94;95 % CI: 0.61-1.43, P = 0.76). While thromboembolic events showed no significant difference in the random-effects model (OR 1.28; 95 % CI: 0.51-4.51, P = 0.46), fixed-effect analysis suggested a statistical significance (OR 1.28; 95 % CI: 1.07-1.55, P = 0.009).

CONCLUSION: Intravenous TXA appears to be an effective adjunctive therapy for managing gastrointestinal bleeding, particularly in reducing rebleeding and failure to control bleeding. However, it does not significantly affect mortality rates, and caution is warranted regarding potential thromboembolic risks. Further research is needed to optimize TXA use and identify high-risk populations to enhance patient outcomes in gastrointestinal bleeding management.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Djoudjou T, Alamri O, Aljuwayr A, et al. Intravenous tranexamic acid in gastrointestinal bleeding: A systematic review and meta-analysis of randomized controlled trials. Am J Emerg Med. 2025. PMID: 40752050. doi:10.1016/j.ajem.2025.07.050

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。